Literature DB >> 6496541

Value of laboratory tests in the differential diagnosis of hypercalcemia.

J C Boyd, J H Ladenson.   

Abstract

Eighteen laboratory tests were compared in the differentiation of primary hyperparathyroidism from hypercalcemia associated with malignancy. Statistical comparisons of the test results were carried out in four patient groups and two control groups. The patient groups evaluated were those with confirmed primary hyperparathyroidism, those with malignancy with hypercalcemia, those with malignancy without hypercalcemia, and those with surgically cured primary hyperparathyroidism. These groups allowed determination of the relative diagnostic values of the tests and a rationale for their value. After exclusion of patients with renal failure from the patient and control groups, these data indicated that the laboratory tests with the greatest differential diagnostic value, in order of efficacy, were: albumin, carboxy-terminal parathyroid hormone, venous pH, cholesterol, chloride, alkaline phosphatase, phosphorus, and the chloride/phosphate ratio. Hemoglobin, hematocrit, and red blood cell count also had some value, particularly in male patients. However, none of these tests individually achieved better than an 81 percent classification accuracy. With application of logistic discriminant analysis, only three tests--albumin, parathyroid hormone, and chloride--were identified as statistically significant in jointly improving the diagnostic separation between these two patient groups. Although the 94.4 percent classification accuracy achieved by use of these three variables in a logistic discriminant function was better than that obtained with any individual variable, incorrect classification was still a significant problem, particularly in the case of patients with malignancy and high concentrations of parathyroid hormone. With the exception of albumin and chloride measurements, the commonly available ancillary laboratory tests proposed to aid this differential diagnosis do not give any more information than the analysis of parathyroid hormone alone and merely add to the increased cost of medical care.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496541     DOI: 10.1016/0002-9343(84)90525-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Chest diseases: sarcoidosis and hypercalcemia.

Authors:  O P Sharma
Journal:  West J Med       Date:  1986-03

2.  Studies on in vivo and in vitro release of intact parathyroid hormone using a new two-site immunochemiluminometric assay.

Authors:  J P Aston; M H Wheeler; R C Brown; I R Curley; J S Woodhead
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

3.  Effects of the intravenous administration of magnesium sulfate on corrected serum calcium level and nephrogenous cyclic AMP excretion in normal human subjects.

Authors:  K Suzuki; K Nonaka; N Kono; K Ichihara; Y Fukumoto; Y Inui; J Miyagawa; T Onishi; C Hayashi; S Tarui
Journal:  Calcif Tissue Int       Date:  1986-11       Impact factor: 4.333

4.  Bedside assessment of hypercalcaemia.

Authors:  F P Muldowney; R Freaney; M J McKenna
Journal:  Ir J Med Sci       Date:  1988-11       Impact factor: 1.568

5.  Primary hyperparathyroidism in Austria: results of an 8-year prospective study.

Authors:  B Niederle; L Stamm; F Längle; E Schubert; W Woloszczuk; R Prager
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

6.  Alteration in osteoblast activity and nutritional vitamin-D deficiency in non-hypercalcemic malignancy.

Authors:  P S Jowell; S Epstein; F Ismail; B Hollis; I R Schwartz
Journal:  Calcif Tissue Int       Date:  1988-01       Impact factor: 4.333

7.  Serum Calcium to Phosphorous (Ca/P) Ratio Is a Simple, Inexpensive, and Accurate Tool in the Diagnosis of Primary Hyperparathyroidism.

Authors:  Bruno Madeo; Elda Kara; Katia Cioni; Silvia Vezzani; Tommaso Trenti; Daniele Santi; Manuela Simoni; Vincenzo Rochira
Journal:  JBMR Plus       Date:  2017-11-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.